# MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

> **NCT01647880** · PHASE2,PHASE3 · TERMINATED · sponsor: **Charite University, Berlin, Germany** · enrollment: 15 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Verum arm receiving Gilenya®
- **DRUG:** Active Comparator receiving Extavia®

## Key facts

- **NCT ID:** NCT01647880
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** delayed recruitment
- **Last updated:** 2021-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647880, "MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01647880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*